Evidence mapPaperPMID 41796409Full record

ArticleDiscover oncology2026

Prognostic nomogram for recurrence free survival in elderly patients with HBV related hepatocellular carcinoma and diabetes from a multicenter study.

Bojun Liu, Han Shi, Linlin Zheng, Xiongwei Cui, Xiaoyan Ding, Caixia Hu

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bojun Liu *Beijing You'an Hospital, Capital Medical University, Beijing, China.
Han Shi *Beijing You'an Hospital, Capital Medical University, Beijing, China.
Linlin ZhengJinan Eco-Environmental Monitoring Center of Shandong Province, Jinan, Shandong, People's Republic of China.
Xiongwei CuiBeijing You'an Hospital, Capital Medical University, Beijing, China. cuixw6@sina.com.
Xiaoyan DingCancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China. dingxiaoyan198111@163.com.
Caixia HuBeijing You'an Hospital, Capital Medical University, Beijing, China. hucaixia1217@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) recurrence after treatment poses a significant burden on patients and their families, particularly in elderly cases (≥ 65 years old) combining type 2 diabetes mellitus (T2DM). T2DM is known to exacerbate the risk of HCC recurrence due to mechanisms such as insulin resistance, oxidative stress, and chronic inflammation. Despite advances in HCC management, including transarterial chemoembolization (TACE), recurrence rates remain high, necessitating better predictive models.

methodsSurvival and recurrence outcomes of HBV-related elderly HCC patients with T2DM undergoing TACE were retrospectively analyzed. Clinical data, including tumor size, tumor number, gamma-glutamyl transferase (GGT), and other laboratory parameters until recurrence free survival (RFS), were collected. Machine learning techniques, including random survival forest (RSF) for variable selection, were employed to develop a predictive nomogram. The model’s performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA) in training and validation cohorts. An external validation cohort consisting of 97 patients from an independent medical center was additionally included to assess model generalizability.

resultsA total of 426 elderly patients with HBV-related HCC and T2DM were enrolled, with a mean age of 69.2 years and a male predominance. Tumor size, tumor number, and GGT were identified as key risk factors for HCC recurrence in these patients. The nomogram demonstrated strong predictive capability for 1-year, 3-year, and 5-year RFS, with area under the curve (AUC) values ranging from 0.616 to 0.696 across cohorts. Calibration and DCA confirmed the model’s accuracy and clinical applicability. Patients classified as high-risk by the model exhibited significantly shorter survival compared to low-risk patients in both training and validation cohorts. The nomogram demonstrated favorable discrimination and calibration in both internal and external validation cohorts, indicating good consistency across datasets.

conclusionsThis study highlights the importance of tumor size, tumor number, and GGT as critical predictors of HCC recurrence in HBV-related patients with T2DM. The proposed machine learning-based nomogram offers a practical tool for personalized risk assessment, enabling clinicians to optimize treatment strategies and improve outcomes in this high-risk population.

Indexed as

Hepatocellular carcinomaMachine learningNomogramPrognosisType 2 diabetes mellitus

Identifiers

PMID41796409
PMCPMC13083750

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.